A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
OPEN TO ACCRUAL
II/III
NCT05691478
bdenardo@BrownHealth.org
